Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.

Abstract

Clazosentan (Ro 61-1790, VML-588 or AXV-034) is under study in clinical trials for the treatment of patients with aneurysmal subarachnoid hemorrhage (SAH) by Actelion Pharmaceuticals. It is a synthetic endothelin (ET) A receptor antagonist that decreases and reverses cerebral vasospasm after experimental SAH. Remarkable dose-dependent effects were observed… (More)
DOI: 10.1517/13543784.17.11.1761

Topics

  • Presentations referencing similar topics